Reply to: Double Trouble from POLG1 and CLCN1 Variants with Intrafamilial Phenotypic Heterogeneity

Funding

Financial Disclosures for the Previous 12 Months: M.G.P. is supported by the Else Kröner‐Fresenius Foundation. S.T. is supported by Deutsche Forschungsgemeinschaft: SFB 936–project C5. T.B. reports honoraria from Pharm Allergan, Ipsen Pharma, and Merz Pharmaceuticals and is a consultant for Pharm Allergan and Merz Pharmaceuticals. He received a grant from Deutsche Forschungsgemeinschaft (FG2494). G.G.K. declares that there are no additional disclosures to report. A.M. reports commercial research support from Pharm Allergan, Ipsen, Merz Pharmaceuticals, and Actelion; honoraria for lectures to Actelion, GlaxoSmithKline, Desitin, and Teva; support from Possehl‐Stiftung (Lübeck, Germany), Margot und Jürgen Wessel Stiftung (Lübeck, Germany), Tourette Syndrome Association (Germany), Interessenverband Tourette Syndrom (Germany), and CHDI; academic research support from Deutsche Forschungsgemeinschaft (projects 1692/3‐1, 4‐1, Sonderforschungsbereich (SFB), 936), and Forschungsgruppen (FOR), 2698 (project numbers 396914663, 396577296, 396474989), and Innovationsausschuss of the Gemeinsamer Bundesausschuss: Translate NAMSE (structural support for the Lübeck Center for Rare Diseases); and royalties for the book Neurogenetics (Oxford University Press).